EHC

Analyst Note: Encompass Health Corporation (EHC)

Date: 2026-06-13 Current Price: $98.03

1. Structural Readiness

State: Context-Only Conservative Entry: — (Awaiting confirmed breakout) Aggressive/Pre-Breakout Entry: — (Not actionable on setup alone) Breakout Level: — (Not yet established) Current Price: $98.03 Extension: — ATR Current: 3.1% (Productive)

2. Thesis Layer

Thesis Status: Tactical / Setup-Led Secular Exposure: None Named Assessment: There is no named macro or secular thesis attached to this specific setup at this date. The investment case is strictly Tactical, driven by the quality of the technical setup (the forming coil) and the immediate fundamental backdrop provided by recent management guidance. We are not assigning a "growth" or "value" label based on external macro narratives but are judging the name solely on its structural readiness and the strength of its Q1 2026 earnings guidance. The conviction weight rests entirely on the execution of the business plan and the technical confirmation of the breakout.

3. Business Overview

Company: Encompass Health Corporation (EHC) Industry: Healthcare / Post-Acute Care Business Model: EHC operates as the nation's largest owner and operator of inpatient rehabilitation hospitals (IRFs) in terms of patients treated, revenues, and facility count. The company delivers post-acute healthcare services through dedicated facilities and home-based care.

Key Operations & Evidence (as of 2026-06-13):

• IRF Footprint: As of March 31, 2026, the company operated 174 IRFs (up from 173 as of Dec 31, 2025), with concentrations in Florida and Texas. The company serves patients in 39 states and Puerto Rico.
• Capacity Expansion: Management is actively expanding capacity. In Q1 2026 alone, they opened a new 49-bed hospital in Irma, SC, and added 44 beds to existing facilities. For the balance of 2026, management expects to open 7 more hospitals (340 beds) and add 100–150 beds to existing hospitals.
• Pipeline: The pipeline of announced projects beyond 2026 includes 11 hospitals with 520 beds, with anticipation of additional small-format hospital announcements.
• Revenue Mix: Approximately 82% of total revenues are derived from Medicare and Medicare Advantage patients. The average age of Medicare patients is approximately 77.
• Service Mix: The business includes Inpatient Rehabilitation, Home Health, and Hospice segments. Home Health and Hospice primarily serve the Southeast and Texas regions.

Management Expectations (Source: Q1 2026 Earnings Transcript, May 1, 2026):

• Guidance Raise: Management raised full-year 2026 guidance based on Q1 results.
• Revenue Expectation: Net operating revenue expected between $6.375 billion and $6.470 billion.
• Profitability Expectation: Adjusted EBITDA expected between $1.35 billion and $1.38 billion; Adjusted EPS expected between $5.89 and $6.11.
• Regulatory Tailwind: Management estimates the 2027 IRF proposed rule (released April 2, 2026) would result in a 2.4% pricing increase for Medicare patients effective October 1, 2026.

4. Archetype and Conviction

Archetype: Quality Compounder Rationale: EHC fits the "Quality Compounder" archetype due to its dominant market position (largest IRF operator), consistent historical bed expansion (78 new hospitals/acquisitions since 2012), and the structural demographic tailwinds it explicitly cites. The business model is characterized by high barriers to entry (licensing, regulatory complexity) and a recurring revenue stream driven by an aging population.

Conviction Stack:

• Thesis Strength: Moderate (Tactical only; no external macro thesis).
• Evidence Quality: High. The evidence base is robust, featuring specific, quantified guidance from the May 1, 2026 earnings call and detailed operational metrics from SEC filings. The guidance raise is a strong signal of management confidence.
• Structural Quality: Strong. The company is executing a clear growth plan (opening 7 hospitals in 2026) and has a defined pipeline. The regulatory environment (2.4% rate increase) is a known structural variable.
• Valuation Context: The financial spine indicates a forward consensus EPS of $6.01 for FY1 and $6.54 for FY2. At a current price of $98.03, the stock trades at approximately 16.3x FY1 consensus and 15.0x FY2 consensus. This valuation appears reasonable for a compounder with double-digit earnings growth expectations and a raised guidance profile.

Conviction Rating: The setup is attractive but requires technical confirmation. The fundamental backdrop is strong, but the technical setup is currently "Forming," meaning it is a watch-list candidate rather than a confirmed entry.

5. Invalidations, Strengtheners, and Gaps

Invalidation Triggers:

• Fundamental: A significant miss on the raised 2026 guidance (e.g., revenue below $6.375B or EPS below $5.89) or a delay in the opening of the 7 planned hospitals would weaken the "Quality Compounder" narrative.
• Regulatory: A final CMS rule that deviates significantly from the proposed 2.4% increase (e.g., a cut or flat rate) would remove a key margin inflector.

Strengtheners:

• Technical: A confirmed breakout above the coil resistance with volume, followed by a retest that holds above the breakout level.
• Fundamental: Further guidance raises in subsequent quarters or faster-than-expected bed openings.
• Operational: Confirmation that the 2027 rate increase is finalized and implemented as expected.

Evidence Gaps:

• Short-Term Catalysts: No specific near-term catalysts (e.g., product launches, M&A announcements) are listed beyond the standard operational expansion.
• Competitive Landscape: No specific data on competitor capacity or market share shifts is provided in the evidence block.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Management raised 2026 guidance citing strong Q1 results; Company is the largest IRF operator with a clear pipeline of 7 new hospitals and 340 beds planned for 2026; 2.4% Medicare rate increase expected to boost margins in Q4 2026. Key risks: Technical setup is still forming and requires breakout confirmation; Regulatory risk if final CMS rule differs from proposed 2.4% increase; Execution risk on opening new facilities on schedule. Expected path: Management expectations suggest continued revenue growth through capacity expansion; structural implications include margin expansion from rate increases and operational leverage. Expected horizon: 6 to 12 months for the thesis to play out as new facilities open and rate changes take effect.